Santos Ltd
.png)
STO Details
-
Updated drilling results: Santos Ltd (ASX: STO) stock surged over 9.5% on June 20, 2016 driven by the ongoing oil rally. The stock slightly fell over 2.3% in the last four weeks (as of June 17, 2016) as STO (operator) faced a mechanical obstruction in the AAL-4X appraisal well and accordingly the Drill Stem Tests (DST) in the K-sand and G-sand reservoirs could not be finished. On the other hand, STO have a track record of delivering positive results, and in the month of May, the first well out of the five well campaign at South Australian Gas, Tirrawarra-93, was cased and suspended as an upcoming producer post the high-side gas pay outcome. At Queensland Gas, Dunadoo-1, the first well out of the three well campaign is targeting sands within the Toolachee Formation and was spudded in May and accordingly the group is further drilling at 2,391 meters in the Nappamerri Group. STO has also started the first LNG from train 2 from GLNG which would enhance its LNG segment performance.
-
Recommendation: We believe STO has more potential to rally in the coming months and maintain a “Buy” on this dividend yield stock at the current price of $4.70
CYBG PLC
CYB Details
-
Brexit seems to impact the stock sentiment: CYBG PLC (ASX: CYB) stock recovered over 5.9% on June 20, 2016 on news of favorable polling towards Brexit remain campaign today against Brexit Leave campaign. The stock has been volatile since the last few days impacted by the fears of a possible Brexit, which might consequently impact the stock’s performance given the group’s heavy exposure in UK markets. On the other hand, the stock has surged over 30.6% (as of June 17, 2016) since its demerger with National Australia Bank given the better than estimated results post the demerger. On the other hand, we believe that the stock would be under pressure in the coming days given the turmoil in the UK markets.
-
Recommendation: The stock is trading at a relatively higher levels and we give an “Expensive” recommendation on the stock at the current price of $5.52
Performance for six months ended on March 2016 (Source: Company Reports)
Mesoblast Limited
.png)
MSB Details
-
On recovery mode: Mesoblast limited (ASX: MSB) stock recovered over 11.7% on June 20, 2016 after facing challenges last week as the stock fell over 44.65% in the last month (as of June 17, 2016). The last week fall seem to be a temporary momentum at the back of Teva’s withdrawal from funding lead product candidate of the group in cardiovascular portfolio - MPC-150-IM for heart failure. On the other hand, MSB already has full worldwide rights for its mesenchymal precursor cell (MPC) technology platform for the cardiovascular field. The group was seeking FDA approval for second navigational catheter system in its Phase 3 program for advanced heart failure.
-
Recommendation: We maintain our “Hold” recommendation on the stock at the current price of $1.185
Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376).The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd currently hold positions in: BHP, BKY, KCN, PDN, and RIO. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.